The MediBeacon renal function system uses an optical skin sensor combined with a proprietary agent that glows in the presence of light. It provides clinicians continuous real-time monitoring of a patient’s kidney function. MediBeacon recently completed initial human clinical trials.
The tracer agent and monitor are not yet approved for sale
The Clinical Need
Real-time point-of-care measurement of renal function will improve patient outcomes in the ICU and the operating suite and achieve optimal dosing strategies for nephrotoxic drug interventions such as chemotherapeutics and imaging contrast agents.
Current Clinical Practice
Current clinical practice for determining renal function is measurement of creatinine in the patient’s blood serum. Serum creatinine concentration rises post kidney insult, however, there are several issues that make this practice much less than optimal.